Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection

Parasite Immunology

Volumn 26, Issue 6-7, 2004, Pages 265-272

  Meraldi, V ^a   Nebie I ^b   Tiono, A B ^b   Diallo, D ^b   Sanogo, E ^b   Theisen, M ^c   Druilhe, P ^d   Corradin, Giampeitro ^a   Moret, R ^a,b   Sirima, B S ^b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b Ctr Natl Rech/Form Paludisme   (Burkina Faso)

^c Statens Serum ^*  (Denmark)

^d INSTITUT PASTEUR   (France)

Author keywords

Antibody; Longitudinal study; Malaria; Plasmodium falciparum; Synthetic peptide; Vaccine

Indexed keywords

GLUTAMATE RICH PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MEROZOITE SURFACE PROTEIN 3; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM EXPORTED PROTEIN 1; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; BLOOD SMEAR; BURKINA FASO; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFANT; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; RISK; SEASONAL VARIATION; SEROPREVALENCE;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BURKINA FASO; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; LONGITUDINAL STUDIES; MALARIA, FALCIPARUM; MALE; OLIGOPEPTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM; PROTOZOA;

EID: 9644289645     PISSN: 01419838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0141-9838.2004.00705.x     Document Type: Article

References (41)

1. Cohen S, McGregor IA & Carrington S. Gamma globulin and acquired immunity to human malaria. Nature 1961; 192: 733-737.
2. Bottius E, Guanzirolli A, Trape JF, Rogier C, Konate L & Druilhe P. Malaria: even more chronic in nature than previously thought; evidence for subpatent parasitaemia detectable by the polymerase chain reaction. Trans R Soc Trop Medical Hyg 1996; 90: 15-19.
3. Roper C, Elhassan IM. Hviid L, et al. Detection of very low level Plasmodium falciparum infections using the nested polymerase chain reaction and a reassessment of the epidemiology of unstable malaria in Sudan. Am J Trop Med Hyg 1996; 54: 325-331.
4. McGregor IA. The passive transfer of human malarial immunity. Am J Trop Med Hyg 1964; 13: 237-239.
5. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991; 45: 297-308.
6. Egan AF, Morris J, Barnish G, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dix 1996; 173: 765-769.
7. Dodoo D, Theander TG, Kurtzhals JA, et al. Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun 1999; 67: 2131-2137.
8. Wang L, Richie TL, Stowers A, Nhan DH & Coppel RL. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun 2001; 69: 4390-4397.
9. Achidi EA, Perlmann H, Salimonu LS, Asuzu MC, Perlmann P & Berzins K. Antibodies to Pf155/RESA and circumsporozoite protein of Plasmodium falciparum in paired maternal-cord sera from Nigeria. Parasite Immunol 1995; 17: 535-540.
10. Fonjungo PN, Elhassan IM, Cavanagh DR, et al. A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Infect Immun 1999; 67: 2975-2985.
11. Okenu DM, Riley EM, Bickle QD, et al. Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun 2000; 68: 5559-5566.
12. Giha HA, Staalsoe T, Dodoo D, et al. Nine-year longitudinal study of antibodies to variant antigens on the surface of Plasmodium falciparum-infected erythrocytes. Infect Immun 1999; 67: 4092-4098.
13. Giha HA, Staalsoe T, Dodoo D, et al. Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett 2000; 71: 117-126.
14. Dodoo D, Staalsoe T, Giha H, et al. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun 2001; 69: 3713-3718.
15. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S & Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000; 68: 2617-2620.
16. Dodoo D, Theisen M, Kurtzhals JA, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000; 181: 1202-1205.
17. Soe S, Theisen M, Roussilhon C, Khin-Saw A & Druilhe P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2003; 72: 147-252.
18. Simmons D, Woollett G, Bergin-Cartwright M, Kay D & Scaife J. A malaria protein exported into a new compartment within the host erythrocyte. EMBO J 1987; 6: 485-491.
19. Kara U, Murray B, Pam C, et al. Chemical characterization of the parasitophorous vacuole membrane antigen QF 116 from Plasmodium falciparum. Mol Biochem Parasitol 1990; 38: 19-23.
20. Sanchez GI, Rogers WO, Mellouk S & Huffman SL. Plasmodium falciparum: exported protein-1, a blood stage antigen, is expressed in liver stage parasites. Exp Parasitol 1994; 79: 59-62.
21. Hope IA, Hall R, Simmons DL, Hyde JE & Scaife JG. Evidence for immunological cross-reaction between sporozoites and blood stages of a human malaria parasite. Nature 1984; 308 (5955): 191-194.
22. Kara UA, Stenzel DJ, Ingram LT, Bushell GR, Lopez JA & Kidson C. Inhibitory monoclonal antibody against a (myristylated) small-molecular-weight antigen from Plasmodium falciparum associated with the parasitophorous vacuole membrane. Infect Immun 1988; 56: 903-909.
23. Sherman IW. Membrane structure and function of malaria parasites and the infected erythrocyte. Parasitology 1985; 91: 609-645.
24. Tolle R, Fruh K, Doumbo O, et al. A prospective study of the association between the human humoral immune response to Plasmodium falciparum blood stage antigen gp190 and control of malarial infections. Infect Immun 1993; 61: 40-47.
25. Charoenvit Y, Majam VF, Corradin G, et al. CD4(+) T-cell-and gamma interferon-dependent protection against murine malaria by immunization with linear synthetic peptides from a Plasmodium yoelii 17-kilodalton hepatocyte erythrocyte protein. Infect Immun 1999; 67: 5604-5614.
26. Charoenvit Y, Mellouk S, Sedegah M, et al. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp Parasitol 1995; 80: 419-429.
27. Meraldi V, Nebié I, Moret R, et al. Recognition of synthetic polypeptides corresponding to the N- and C-terminal fragments of Plasmodium falciparum Exp-1 by T-cells and plasma from human donors from African endemic areas. Parasite Immunol 2002; 24: 141-150.
28. Meraldi V. Long synthetic polypeptides for the characterization of the antigenicity and immunogenicity of malarial antigens in the development of a subunit vaccine. PhD Thesis 2002; University of Lausanne, Switzerland.
29. Marsh K, Otoo L, Hayes RJ, Carson DC & Greenwood BM. Antibodies to blood stage antigens of Plasmodium falciparum in rural Gambians and their relation to protection against infection. Trans R Soc Trop Medical Hyg 1989; 83: 293-303.
30. Atherton E, Logan CJ & Sheppard RC. Peptide synthesis, Part 2. Bioorg Chem 1979; 8: 350-351.
31. Roggero MA, Filippi B, Church P, et al. Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the Plasmodium falciparum CS protein. Mol Immunol 1995; 32: 1301-1309.
32. Theisen M, Dodoo D, Toure-Balde A, et al. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 2001; 69: 5223-5229.
33. Riley EM, Olerup O, Bennett S et al. MHC and malaria: the relationship between HLA class II alleles and immune responses to Plasmodium falciparum. Int Immunol 1992; 4: 1055-1063.
34. Taylor RR, Egan A, McGuinness D et al. Selective recognition of malaria antigens by human serum antibodies is not genetically determined but demonstrates some features of clonal imprinting. Int Immunol 1996; 8: 905-915.
35. de Stricker K, Vuust J, Jepsen S, Oeuvray C & Theisen M. Conservation and heterogeneity of the glutamate-rich protein (GLURP) among field isolates and laboratory lines of Plasmodium falciparum. Mol Biochem Parasitol 2000; 111: 123-130.
36. McColl DJ & Anders RF. Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 1997; 90: 21-31.
37. Theisen M, Soe S, Oeuvray C, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998; 66: 11-17.
38. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994; 84: 1594-1602.
39. Bouharoun-Tayoun H, Oeuvray C, Lunel F & Druilhe P. Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 1995; 182: 409-418.
40. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T & Druilhe P. Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 1990; 172: 1633-1641.
41. Blackman MJ & Holder AA. Use of a recombinant baculovirus product to measure naturally-acquired human antibodies to disulphide-constrained epitopes on the P. falciparum merozoite surface protein-1 (MSP1). FEMS Immunol Medical Microbiol 1993; 6: 307-315.